Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Broad-Spectrum Antiviral Therapeutics

Figure 10

DRACOs appeared promising when administered via intranasal (i.n.) injection in proof-of-concept trials with adult BALB/c mice.

(A) 0.5 mg PKR-Apaf DRACO administered i.n. to adult BALB/c mice penetrated the lungs and persisted over 24 hours. Averages of 3 mice per data point are plotted, and error bars show s.e.m. (B) PTD-PKR-Apaf, TAT-PKR-Apaf, and ARG-PKR-Apaf DRACOs administered i.n. on day 0 reduced the morbidity in mice challenged i.n. with 1 LD50 influenza H1N1 A/PR/8/34.

Figure 10